University of Utah Research Foundation

Glycomira Therapeutics, Inc.

Won Yong Lee

Glenn D Prestwich

Thomas P Kennedy

Wanjian Jia

Siam Oottamasathien

Justin Savage

Lindsi McCoard

Lindsi M Roundy

Abigail Pulsipher

Siam Oottamasathien, Viii

Justin Rodney Savage

Described herein are methods for reducing or maintaining the size of a tumor in a subject, where the method involves exposing the tumor to ionizing radiation and administering to the subject a modified hyaluronan or a pharmaceutically acceptable salt or ester. The use of the modified hyaluronan enhances or potentiates the effect of ionizing radiation used in cancer treatment. Additionally, the methods described herein prevent or reduces tumor regrowth in the subject after exposing the tumor to ionizing radiation and administration of the modified hyaluronan to the subject.

Methods for potentiating cancer treatment using ionizing radiation

Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy

Described herein are pharmaceutical compositions composed of low molecular weight sulfated hyaluronan.

Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan

Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising a. a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and at least one primary C-6 hydroxyl position of an N-acetyl-glucosamine residue comprising an alkyl group or fluoroalkyl group; b. a partially or fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof, or a combination thereof.

Methods for treating or preventing urological inflammation

Growing community of inventors

Salt Lake City, UT, United States of America

Won Yong Lee